Skip to content

Effect of Bach Flower treatment on hope and quality of life in patients with Advanced Cancer

Effectiveness of Bach Flower therapy on hope and health-related quality of life of patients with Advanced Cancer: randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8q6z6kq
Enrollment
Unknown
Registered
2022-05-19
Start date
2022-06-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasm Metastasis

Interventions

Intervention group (IG), the participants will use the florals selected for the research in a bottle containing: two drops of each Bach Flower Therapy (Gorse, Cherry plum, Mimulus, Wild oat, Mustard,

Sponsors

Leonel dos Santos Silva
Lead Sponsor
Universidade Federal do Paraná
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Be over 18 years old; have a histologically proven diagnosis of any type of advanced (stage IV) cancer; Eastern Cooperative Oncology Group (ECOG): 0, 1, 2 or 3 characterized as: 0 (fully active); 1 (restricted from strenuous physical activity and able to perform work of a light or sedentary nature); 2 (self-care capacity without working conditions, remains out of bed 50% of the time) and 3 (limited self-care capacity, remains 50% of the time in bed or chair rest)

Exclusion criteria

Exclusion criteria: Continuous use of anxiolytic and antidepressant medications; use of some integrative or complementary health practice such as flower essences, chromotherapy, aromatherapy, acupuncture, reiki, therapeutic touch, among others; unable to maintain verbal and/or written communication by the assessment of the Eastern Cooperative Oncology Group (ECOG) 4 performance scale (completely limited and unable to perform self-care activities, totally confined to bed or chair)

Design outcomes

Primary

MeasureTime frame
Increase in hope and health-related quality of life score of patients with advanced cancer. These will be measured with the respective Herth Hope Index (hope) and FACIT-Pal (health-related quality of life) instruments in the group of participants who undergo intervention or placebo

Secondary

MeasureTime frame
Reduction or maintenance of hope scores and health-related quality of life in patients with advanced cancer

Countries

Brazil

Contacts

Public ContactComitê de Ética em Pesquisa Complexo Hospital de Clínicas

Universidade Federal do Paraná

cep@hc.ufpr.br+55 41 3360-1041

Outcome results

None listed

Source: REBEC (via WHO ICTRP)